natgillin/translations-raw huggingface dataset:
I studiet blev 460 voksne, som var i behandling med 2 nukleosid reverse-transkriptasehæmmere og mindst en PI og hvis plasma-hiv-1-RNA-niveau havde været lavere end 200 c/ml i mindst 6 måneder, skiftet til behandling fra proteasehæmmeren til enten Viramune (155 patienter), til efavirenz (156 patienter) eller til abacavir (149 patienter). 
The study randomly assigned 460 adults who were taking two nucleoside reverse-transcriptase inhibitors and at least one PI and whose plasma HIV-1 RNA levels had been less than 200 c/ml for at least the previous six months to switch from the PI to Viramune (155 patients), efavirenz (156), or abacavir (149).
Sjælden (kan forekomme hos op til 1 ud af 1.000 patienter): - leverbetændelse (hepatitis) - nedsat antal af røde blodlegemer (anæmi) 
Rare (may affect up to 1 in 1000 people): - inflammation of the liver (hepatitis) - decreased numbers of red blood cells (anaemia)
Serum niveauet af nevirapin kan være reduceret ved samtidig brug af naturlægemidlet, perikon (Hypericum perforatum). 
Serum levels of nevirapine can be reduced by concomitant use of the herbal preparation St. John's Wort (Hypericum perforatum).
Beregning af mængden af Viramune oral suspension (50 mg/5 ml) til pædiatrisk dosering efter den tougers optrapningsperiode: 
Calculation of the volume of Viramune oral suspension (50 mg/5 ml) required for paediatric dosing after the two weeks lead-in period.
Hvis du får symptomer, som kan tyde på, at leveren har taget skade så som - appetitløshed - kvalme - opkastning - gulsot (huden bliver gul) - mavesmerter skal du stoppe med at tage Viramune, og du skal straks kontakte lægen. 
If you experience symptoms suggesting damage of the liver, such as - loss of appetite, - feeling sick (nausea), - vomiting, - yellow skin (jaundice), - abdominal pain you should discontinue taking Viramune and must contact your doctor immediately.
- Uønskede hændelser 
- Death - Adverse events
Vægtinterval (kg) for patienter < 8 år 
Weight Range (kg) for patients < 8 yrs of age
Autoimmune lidelser (såsom Graves sygdom og autoimmun hepatitis) er også set; tiden til udbrud er mere variabel og kan være mange måneder efter initiering af behandling. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
På baggrund af erfaring fra kliniske studier med Viramune 200 mg tabletter og oral suspension med 361 pædiatriske patienter, hvor hovedparten fik kombinationsbehandling med ZDV og/eller ddl, er de bivirkninger, som hyppigst er relateret til nevirapin, tilsvarende dem, som er set hos voksne. 
Based on clinical study experience with Viramune immediate-release tablets and oral suspension of 361 paediatric patients the majority of which received combination treatment with ZDV or/and ddI, the most frequently reported adverse events related to nevirapine were similar to those observed in adults.
Nevirapin koncentrationer er ikke blevet målt. 
Nevirapine concentrations not measured, no effect is expected.
Patienter, der oplever alvorligt udslæt eller udslæt ledsaget af konstitutionelle symptomer såsom feber, blæredannelse, orale læsioner, conjunctivitis, ødemer i ansigt, muskel- og ledsmerter eller generelt ubehag, skal ophøre med lægemidlet og omgående søge lægehjælp. 
Any patient experiencing severe rash or a rash accompanied by constitutional symptoms such as fever, blistering, oral lesions, conjunctivitis, facial oedema, muscle or joint aches, or general malaise should discontinue the medicinal product and immediately seek medical evaluation.
Samtidig administration af telaprevir og CYP3Aog/eller P-gp-inducere kan nedsætte telaprevir plasmakoncentrationen. 
Coadministration of telaprevir and medicinal products that induce CYP3A and/or P-gp may decrease telaprevir plasma concentrations.
Ryst flasken grundigt før brug. 
Shake the bottle well before you take your medicine.
leversvigt påkrævende transplantation, er blevet rapporteret hos ikke hiv-smittede personer, som fik multiple doser af Viramune i forbindelse med post-eksponerings-profylakse (PEP), en ikke godkendt anvendelse. 
Post-Exposure-Prophylaxis: Serious hepatotoxicity, including liver failure requiring transplantation, has been reported in HIV-uninfected individuals receiving multiple doses of Viramune in the setting of post-exposure-prophylaxis (PEP), an unapproved use.
Dosis for voksne er 20 ml (200 mg) 1 gang dagligt i de første 14 dage af behandlingen (optrapningsfase). 
The dose for adults is 20 ml (200 mg) once a day for the first 14 days of treatment (”lead in” period).
Fremstillernes anbefalede dosis bør følges ved samtidig behandling. 
For concomitantly administered therapy, the manufacturers recommended dose should be followed.
Ryst flasken forsigtigt. 
Shake the bottle gently.
Viramune bruges til behandling af hiv-1-smittede voksne, unge og børn i alle aldre. 
Viramune is indicated for the treatment of HIV-1 infected adults, adolescents, and children of any age.
I dette åbne studie blev 443 patienter, der allerede var på et antiviralt regime med Viramune 200 mg to gange dagligt og med hiv-1-rna < 50 kopier/ml, randomiseret i et 2:1-forhold til at få Viramune 400 mg i depotform én gang dagligt eller Viramune 200 mg to gange dagligt. 
In this open-label study, 443 patients already on an antiviral regimen containing Viramune 200 mg immediate-release twice daily with HIV-1 RNA < 50 copies/ml were randomised in a 2:1 ratio to Viramune 400 mg prolongedrelease once daily or Viramune 200 mg immediate-release twice daily.
Et steady state studie blev udført, hvilket sammenlignede 46 patienter med let (n=17; Ishak Score 1-2), moderat (n=20; Ishak Score 3-4), eller alvorlig (n=9; Ishak Score 5-6, Child-Pugh A i 8 patienter, score for 1 Child-Pugh er ikke tilgængelig) leverfibrose, som målestok for hepatisk dysfunktion. 
Hepatic impairment: A steady state study comparing 46 patients with mild (n=17: Ishak Score 1-2), moderate (n=20; Ishak Score 3-4), or severe (n=9; Ishak Score 5-6, Child-Pugh A in 8 pts., for 1 Child-Pugh score not applicable) liver fibrosis as a measure of hepatic impairment was conducted.
Brug af Viramune sammen med mad og drikke Du kan tage Viramune sammen med mad og drikke eller uden mad og drikke. 
Taking Viramune with food and drink There are no restrictions on taking Viramune with food and drink.
Viramune bør anvendes i kombination med mindst to andre antiretrovirale lægemidler. 
Viramune should be combined with at least two additional antiretroviral agents.
Cmean_max af nevirapin var 2.060 ng/ml målt gennemsnitligt 24,5 timer efter administration af 400 mg Viramune depottabletter. 
The mean peak plasma concentration of nevirapine was 2,060 ng/ml measured at a mean 24.5 hours after administration of 400 mg Viramune prolongedrelease tablets.
Patienter, som afbryder behandlingen med nevirapin i mere end 7 dage, skal genoptage behandlingen med den anbefalede 2 ugers optrapningsperiode. 
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing regimen using the two week lead-in period.
Der foreligger ingen data for, hvorvidt Viramune 100 mg kan bruges i stedet for 400 mg depottabletter, og voksne bør derfor ikke tage 100 mg depottabletter. 
There are no data on the interchangeability of 100 mg compared to 400 mg prolonged-release tablets and therefore, 100 mg prolonged-release tablets should not be taken by adults.
1.216 antiretroviralterapi-naive patienter med plasma hiv-1-RNA ved baseline >5.000 kopier/ml blev i 48 uger allokeret til Viramune 400 mg én gang daglig, Viramune 200 mg to gange daglig, efavirenz 600 mg én gang daglig eller Viramune (400 mg) og efavirenz (800 mg) én gang daglig, plus stavudin og lamivudin. 
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to Viramune 400 mg once daily, Viramune 200 mg twice daily, efavirenz 600 mg once daily, or Viramune (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
Denne optrapningsperiode periode har vist sig at mindske hyppigheden af udslæt og bør derfor benyttes. 
This lead-in period should be used because it has been found to lessen the frequency of rash.
Følgende bivirkninger er set hos patienter i vedligeholdelsesbehandling med Viramune depottabletter én gang dagligt: 
The side effects described below have been experienced by patients given Viramune prolonged-release tablets once daily in the maintenance phase:
Nevirapin har en gennemsnitlig EC50-værdi (koncentration for 50 % hæmmet) på 63 nM mod et panel af gruppe M hiv-1 isolater fra typerne A, B, C, D, F, G og H, og de cirkulerende rekombinante former (CRF), CRF01_AE, CRF02_AG og CRF12_BF replikeret i humane embryonale nyre 293-celler. 
Nevirapine had a median EC50 value (50% inhibitory concentration) of 63 nM against a panel of group M HIV-1 isolates from clades A, B, C, D, F, G, and H, and circulating recombinant forms (CRF), CRF01_AE, CRF02_AG and CRF12_BF replicating in human embryonic kidney 293 cells.
Nevirapin Cmin  1,28 
Nevirapine Cmin  1.28
Patienter, der allerede får Viramune 200 mg to gange dagligt i kombination med andre antiretrovirale midler, kan skifte over til Viramune 400 mg depottabletter én gang dagligt i kombination med andre antiretrovirale midler uden en lead-in periode med Viramune 200 mg. 
Patients already on a regimen of Viramune immediate-release twice daily in combination with other antiretroviral agents can be switched to Viramune 400 mg prolonged-release tablets once daily in combination with other antiretroviral agents without a lead-in period of Viramune immediate-release.
Hjælpestoffer: Indeholder saccharose, sorbitol, methylparahydroxybenzoat, propylparahydroxybenzoat (se indlægssedlen for yderligere information) 
Excipients: includes sucrose, sorbitol, methyl parahydroxybenzoate, propyl parahydroxybenzoate (see leaflet for further information)
Hvis dit barn får nogen form for udslæt i denne periode, må dit barns dosis ikke øges, men du skal kontakte barnets læge i stedet. 
If your child develops any rash during this period, do not increase the dose but consult your child's doctor.
Der er ikke udført lægemiddelinteraktionsstudier med telaprevir og nevirapin, men interaktionsstudier af telaprevir og en NNRTI med lignende metaboliseringsvej som nevirapin viste reducerede niveauer af begge. 
No drug-drug interaction study of telaprevir with nevirapine has been conducted, however, interaction studies of telaprevir with an NNRTI with a similar metabolic pathway as nevirapine demonstrated reduced levels of both.
Viramune 100 mg depottabletter fås i plastbeholder med 90 depottabletter. 
Viramune 100 mg prolonged-release tablets are supplied in bottles with 90 prolongedrelease tablets.
Viramune fås også som 200 mg tabletter til ældre børn og især unge, der vejer over 50 kg eller har en legemsoverfladeareal på mere end 1,25 m². 
Viramune is also available as 200 mg tablets for older children, particularly adolescents, weighing more than 50 kg or having a body surface of more than 1.25 m2.
Der er bivirkninger, som kræver afbrydelse af Viramune-behandling, se pkt. 
There are toxicities that require interruption of Viramune therapy (see section 4.4).
Resultatet af et 48-ugers sydafrikansk studie BI1100.1368 bekræftede, at i patientgrupperne doseret med 4 mg/kg og 150 mg/m² nevirapin var dosis veltolereret og effektiv i behandlingen af antiretroviralnaive pædiatriske patienter. 
Results of a 48-week analysis of the South African study BI 1100.1368 confirmed that the 4/7 mg/kg and 150 mg/m2 nevirapine dose groups were well tolerated and effective in treating antiretroviral naive paediatric patients.
Patienterne skal instrueres i, at de ikke må starte med Viramune depottabletter, før et eventuelt udslæt opstået i den 14-dages optrapningsperiode med Viramune med umiddelbar frigivelse, er forsvundet. 
Patients should be instructed that they should not begin Viramune prolonged-release tablets until any rash that has occurred during the 14-day lead-in period of Viramune immediate-release has resolved.
- Øvrige indholdsstoffer: - carbomer, - methylparahydroxybenzoat, - propylparahydroxybenzoat, - sorbitol, - saccharose, - polysorbat 80, - natriumhydroxid og - vand. 
- The other ingredients are: carbomer, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sorbitol, sucrose, polysorbate 80, sodium hydroxide and water.
Beregning af mængden af Viramune oral suspension (50 mg/5 ml) til en pædiatrisk dosering baseret på dosen 150 mg/m² legemsoverfladeareal: 
Calculation of the volume of Viramune oral suspension (50 mg/5 ml) required for paediatric dosing on a body surface basis of 150 mg/m
Beholderen indeholder 30 depottabletter. 
Bottles contain 30 prolonged-release tablets.
Samtidig prednisonbrug (40 mg/dag i de første 14 dage af Viramune administrationen) har vist sig ikke at nedsætte tilfældene af nevirapin-associeret udslæt, og kan være associeret med en stigning tilfælde og alvorlighed af udslæt under de første 6 uger af nevirapin-behandlingen. 
Concomitant prednisone use (40 mg/day for the first 14 days of Viramune administration) has been shown not to decrease the incidence of nevirapine-associated rash, and may be associated with an increase in incidence and severity of rash during the first 6 weeks of nevirapine therapy.
Der sås ikke signifikant forskel på virkningen i ”nevirapin 2 gange daglig”-regimegruppen og efavirenzregimegruppen (p = 0,091) bedømt ud fra behandlingssvigt, eller tilfælde af behandlingssvigt, herunder virologisk svigt. 
The nevirapine twice daily regimen and the efavirenz regimen were not significantly different (p=0.091) in terms of efficacy as measured by treatment failure, or any component of treatment failure including virological failure.
200 (2 x 100 mg) 300 (3 x 100 mg) 
200 (2 x 100 mg)
Nevirapin er en ikke-nukleosid revers transkriptasehæmmer (NNRTI) af hiv-1. 
Nevirapine is a NNRTI of HIV-1.
Nevirapin har vist sig at inducere leverens cytokrom P450-metaboliske enzymer. 
Nevirapine has been shown to be an inducer of hepatic cytochrome P450 metabolic enzymes.
Nevirapins anti-hiv-1-aktivitet blev in vitro hæmmet af anti-HBV-midlet adefovir og af anti-HCV-midlet ribavirin. 
The anti-HIV-1 activity of nevirapine was antagonized by the anti-HBV medicinal product adefovir and by the anti-HCV medicinal product ribavirin in vitro.
Baseline (gennemsnit) n = 503 
Baseline (mean) n=503
Ketoconazol AUC  0,28 (0,20-0,40) Ketoconazol Cmin ND Ketoconazol Cmax  0,56 (0,42-0,73) 
Ketoconazole AUC  0.28 (0.20Ketoconazole Cmin ND Ketoconazole Cmax  0.56 (0.42
Immunsystemet Almindelig: 
Immune system disorders
INFORMATION I BRAILLESKRIFT Viramune 200 mg 
INFORMATION IN BRAILLE Viramune 200 mg
I humane in vivo studier og in vitro studier med humane levermikrosomer har vist, at nevirapin i høj grad biotransformeres via cytokrom P450 (oxidativ) metabolisme til adskillige hydroxylerede metabolitter. 
Biotransformation and elimination: In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 (oxidative) metabolism to several hydroxylated metabolites.
Hepatobiliært 
Hepato-biliary
Ved behandling af patienter, der er smittet med tuberkulose, som samtidig får Viramune, bør anvendelse af rifabutin overvejes istedet. 
Physicians needing to treat patients co-infected with tuberculosis and using a Viramune containing regimen may consider coadministration of rifabutin instead.
Den geometriste middelværdi ratio for Viramune i depotform i forhold til Viramune 200 mg var ~90 % for Cmin,ss og for AUCss med 90 % konfidensintervaller inden for 80 %-125 %; ratio for Cmax,ss var lavere og konsistent med én gang dagligt depotdoseringsform. 
The observed geometric mean ratios of Viramune prolonged-release to Viramune immediate-release were ~90 % for Cmin,ss and AUCss with 90% confidence intervals within 80 %-125 %; the ratio for Cmax,ss was lower and consistent with a once-daily prolonged-release dosage form.
Risikoen for hepatiske bivirkninger er størst i de første 6 uger af behandlingen. 
The risk of hepatic reactions is greatest in the first 6 weeks of therapy.
Sådanne reaktioner kan opstå i form af anafylaksi (en alvorlig form for allergisk reaktion) med symptomer som: - udslæt - hævelse i ansigtet - vejrtrækningsbesvær (bronkospasme - astmalignende gener) - anafylaktisk shock 
Such reactions may appear in the form of anaphylaxis (a severe form of allergic reaction) with symptoms such as: - rash - swelling of the face - difficulty breathing (bronchial spasm) - anaphylactic shock
Følgende bivirkninger, som kan være forårsaget af indgivelsen af Viramune, er blevet rappoteret. 
The following adverse reactions which may be causally related to the administration of Viramune have been reported.
Ingen signifikant virkning på rifabutin og Viramune gennemsnitlige farmakokinetiske (PK) parametre er set. 
No significant effect on rifabutin and Viramune mean PK parameters is seen.
Viramune er kontraindiceret hos patienter med alvorlig hepatisk insufficiens (ChildPugh C, se pkt. 
Viramune is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Nevirapin skal seponeres permanent hos enhver patient, som udvikler et alvorligt udslæt eller udslæt ledsaget af konstitutionelle symptomer (såsom feber, blæredannelse, orale læsioner, conjunctivitis, ødemer i ansigt, muskel- eller ledsmerter eller generel utilpashed) inkluderende Stevens-Johnsons syndrom eller toksisk epidermal nekrolyse. 
Nevirapine must be permanently discontinued in any patient experiencing severe rash or a rash accompanied by constitutional symptoms (such as fever, blistering, oral lesions, conjunctivitis, facial oedema, muscle or joint aches, or general malaise), including Stevens-Johnson syndrome, or toxic epidermal necrolysis.
Lactose: Ved den maksimale, anbefalede daglige dosis af Viramune tabletter indtages 636 mg lactose. 
Lactose: Viramune tablets contain 636 mg of lactose per maximum recommended daily dose.
Stevens-Johnsons syndrom/toksisk epidermal nekrolyse (som kan være letal) (0,2 %), angioødem, urticaria 
Uncommon Stevens-Johnson Syndrome/toxic epidermal necrolysis (which may be fatal) (0.2 %), angioedema, urticaria
Efter 14 dage er den sædvanlige dosis én Viramune 400 mg depottablet én gang dagligt. 
After 14 days, the usual dose is one 400 mg prolonged-release tablet once a day.
Efter 14 dage er dosis normalt 1 tablet på 200 mg 2 gange daglig. 
After 14 days, the usual dose is one 200 mg tablet twice a day.
Resultatet tyder på, at ved at supplere nevirapinbehandlingen med en ekstra dosis på 200 mg Viramune efter hver dialysebehandling kan effekten af dialyse på nevirapinclearance afhjælpes. 
The results suggest that supplementing nevirapine therapy with an additional 200 mg dose of Viramune following each dialysis treatment would help offset the effects of dialysis on nevirapine clearance.
Patienter med svær hepatisk insufficiens (Child-Pugh C) eller der forud for behandling har ASAT eller ALAT > 5 ULN før baseline ASAT/ALAT er stabiliseret < 5 ULN. 
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN.
Den kliniske virkning af Viramune depottabletter er baseret på 48 ugers data fra et randomiseret, dobbeltblindet, dobbeltdummy-, fase III-studie (VERxVE - studie 1100.1486) med behandlingsnaive patienter og 24 ugers data fra et randomiseret, åben-label studie hos patienter, der er overgået fra to gange dagligt Viramune 200 mg tabletter til én gang dagligt Viramune depottabletter (TRANxITION -studie 1100.1526). 
The clinical efficacy of Viramune prolonged-release is based on 48-week data from a randomised, double-blind, double-dummy phase 3 study (VERxVE - study 1100.1486) in treatment-naïve patients and on 24-week data from a randomised, open-label study in patients who transitioned from Viramune immediate-release tablets administered twice daily to Viramune prolonged-release tablets administered once daily (TRANxITION - study 1100.1526).
Absolut biotilgængelighed hos 12 raske voksne efter en enkelt dosis var 93±9 % (gennemsnitlig SD) efter en 50 mg tablet og 91±8 % efter peroral opløsning. 
Absolute bioavailability in 12 healthy adults following single-dose administration was 93  9 % (mean SD) for a 50 mg tablet and 91  8% for an oral solution.
Absolut biotilgængelighed hos 12 raske voksne efter en enkelt dosis var 93±9% (gennemsnitlig SD) efter en 50 mg tablet og 91±8% efter peroral opløsning. 
Absolute bioavailability in 12 healthy adults following single-dose administration was 93  9 % (mean SD) for a 50 mg tablet and 91  8 % for an oral solution.
HDPE-beholder (high density polyethylen) med plastiklåg og folieforsegling. 
High density polyethylene (HDPE) plastic bottle, with a plastic cap and an induction foil seal liner.
ANTIBIOTIKA Clarithromycin 500 mg 2 gange dagligt 
ANTIBIOTICS Clarithromycin 500 mg BID
Der sås ikke signifikant forskel på virkningen i ”nevirapin 2 gange daglig”regimegruppen og efavirenz-regimegruppen (p = 0,091) bedømt ud fra behandlingssvigt, eller tilfælde af behandlingssvigt, herunder virologisk svigt. 
The nevirapine twice daily regimen and the efavirenz regimen were not significantly different (p= 0.091) in terms of efficacy as measured by treatment failure, or any component of treatment failure including virological failure.
Til mindre børn findes en oral suspension (flydende form). 
For smaller children an oral suspension liquid form is available.
Rekommendationer ved coadministration med Viramune 
Recommendations concerning coadministration
Baseline (gennemsnit) n = 505 
Baseline (mean) n=505
Mosteller-formel: Legemsoverfladeareal (m 
Mosteller Formula: BSA (m
Viramune oral suspension indeholder 150 mg saccharose pr. ml. 
Viramune oral suspension contains 150 mg sucrose per ml.
Den terapeutiske virkning af stoffer, der metaboliseres af P450 bør derfor monitoreres nøje ved co-administration med nevirapin. 
Careful monitoring of the therapeutic effectiveness of P450 metabolised medicinal products is recommended when taken in combination with nevirapine.
200 mg 
200 mg QD
Hos nogle patienter kan et hududslæt, der viser sig som blærer på huden, være alvorligt og livstruende (Stevens-Johnsons syndrom og toksisk epidermal nekrolyse) og dødsfald har fundet sted. 
However, in some patients a rash, which appears as a blistering skin reaction, can be severe or life-threatening (Stevens-Johnson syndrome and toxic epidermal necrolysis) and deaths have been recorded.
Nevirapins AUC0-24,ss og Cmin,ss målt efter 19 dages fastende dosering af Viramune 400 mg depottabletter én gang dagligt, var henholdsvis ca. 80 % og 90 % af AUC0-24,ss og Cmin,ss målt ved dosering af Viramune 200 mg tabletter to gange dagligt. 
The nevirapine AUC0-24,ss and Cmin,ss measured after 19 days of fasted dosing of Viramune 400 mg prolonged-release tablets once daily were approximately 80 % and 90 %, respectively, of the AUC0-24,ss and Cmin,ss measured when patients were dosed with Viramune 200 mg immediate-release tablets twice daily.
Tabel 2: Vedligeholdelsesfase med Viramune depottabletter 
Table 2: Maintenance phase of Viramune prolonged-release
Studier med behandlingserfarne patienter 
Studies in treatment-experienced patients
Følgende tilfælde har også været rapporteret, når Viramune er blevet taget i kombination med andre retrovirale midler: - fald i antal røde blodlegemer eller i blodplader - betændelse i bugspytkirtlen - nedsat eller abnorm følsomhed i huden 
The following events have also been reported when Viramune has been used in combination with other antiretroviral agents: - decreased numbers of red blood cells or platelets - inflammation of the pancreas - decrease in or abnormal skin sensations
Til små børn og nyfødte, findes der en oral suspension. 
For younger children starting from birth an oral suspension is available.